Literature DB >> 27727233

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Angus G Dalgleish, Justin Stebbing, Douglas J A Adamson, Seema Safia Arif, Paolo Bidoli, David Chang, Sue Cheeseman, Robert Diaz-Beveridge, Carlos Fernandez-Martos, Rob Glynne-Jones, Cristina Granetto, Bartomeu Massuti, Karen McAdam, Raymond McDermott, Andrés J Muñoz Martín, Demetris Papamichael, Roberto Pazo-Cid, Jose M Vieitez, Alberto Zaniboni, Kevin J Carroll, Shama Wagle, Andrew Gaya, Satvinder S Mudan.   

Abstract

Entities:  

Year:  2016        PMID： 27727233      PMCID： PMC5117801          DOI： 10.1038/bjc.2016.342

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Correction to: British Journal of Cancer (2016) 115, 789–796; doi:10.1038/bjc.2016.271 Upon publication of the above paper in the British Journal of Cancer, the authors identified an error in one of their affiliations. The authors would like to apologise for this mistake. The correct affiliation for Andrés J Muñoz Martín is ‘Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.'
  6 in total

1.  Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.

Authors:  Sumiyuki Nishida; Akihiro Tsuboi; Atsushi Tanemura; Toshinori Ito; Hiroko Nakajima; Toshiaki Shirakata; Soyoko Morimoto; Fumihiro Fujiki; Naoki Hosen; Yusuke Oji; Atsushi Kumanogoh; Ichiro Kawase; Yoshihiro Oka; Ichiro Azuma; Satoshi Morita; Haruo Sugiyama
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

2.  Anti-Tumor Effect of Heat-Killed Bifidobacterium bifidum on Human Gastric Cancer through Akt-p53-Dependent Mitochondrial Apoptosis in Xenograft Models.

Authors:  SukJin Kim; Hwan Hee Lee; Wonhyeok Choi; Chang-Ho Kang; Gun-Hee Kim; Hyosun Cho
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

Review 3.  Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.

Authors:  Yiyin Zhang; Chao Yang; He Cheng; Zhiyao Fan; Qiuyi Huang; Yu Lu; Kun Fan; Guopei Luo; Kaizhou Jin; Zhengshi Wang; Chen Liu; Xianjun Yu
Journal:  J Hematol Oncol       Date:  2018-01-31       Impact factor: 17.388

4.  Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity.

Authors:  Angus G Dalgleish; Satvinder Mudan; Alberto Fusi
Journal:  J Transl Med       Date:  2018-08-14       Impact factor: 5.531

Review 5.  Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends".

Authors:  Thomas-Oliver Kleen; Alicia A Galdon; Andrew S MacDonald; Angus G Dalgleish
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561

6.  Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

Authors:  Angus G Dalgleish; Emma McLean; Nirav Patel; Najib Rahman
Journal:  Respir Med Case Rep       Date:  2019-11-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.